Oncogenic osteomalacia - A complex dance of factors

New England Journal of Medicine

Volumn 348, Issue 17, 2003, Pages 1705-1708

  Carpenter, Thomas O ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; INDIUM 111; OCTREOTIDE; OSTEOCALCIN; PARATHYROID HORMONE; PENTETREOTIDE; PHOSPHATE; VITAMIN D;

BENIGN TUMOR; BONE TURNOVER; CANCER SURGERY; CARCINOGENICITY; CLINICAL FEATURE; DISEASE COURSE; EDITORIAL; ENZYME ACTIVITY; FAMILY HISTORY; HEMANGIOPERICYTOMA; HORMONE BLOOD LEVEL; HUMAN; INVASIVE CARCINOMA; MEDIATOR; MUTATION; OSTEOMALACIA; PARANEOPLASTIC SYNDROME; PATHOPHYSIOLOGY; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; TUMOR LOCALIZATION; VITAMIN D RESISTANT RICKETS;

ADULT; CHILD; DIAGNOSIS, DIFFERENTIAL; FIBROBLAST GROWTH FACTORS; GENETIC DISEASES, X-LINKED; HUMANS; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIA, FAMILIAL; OSTEOMALACIA; PARANEOPLASTIC SYNDROMES;

EID: 0037464509     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe030037     Document Type: Editorial

References (14)

1. Jonsson KB, Zahradnik K, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63.
2. Carpenter TO. New perspectives on the biology and treatment ofX-linked hypophosphatemic rickets. Pediatr Clin North Am 1997; 44:443-66.
3. Nguyen BD, Wang EA. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med 1999;24:130-1.
4. Seufert J, Ebert K, Müller J, et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 2001;345:1883-8.
5. Agus ZS. Oncogenic hypophosphatemic osteomalacia. Kidney Int 1983;24:113-23.
6. Shane E, Parisien M, Henderson JE, et al. Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res 1997;12: 1502-11.
7. Yeung SJ, McCutcheon IE, Schultz P, Gagel RF. Use of long-term intravenous phosphate infusion in the palliative treatment of tumor-induced osteomalacia. J Clin Endocrinol Metab 2000;85:549-55.
8. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors: a polymorphous group causing osteomalacia or rickets. Cancer 1987;59:1442-54.
9. Drezner MK. Tumor-induced osteomalacia. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 1999:331-7.
10. Cheng CL, Ma J, Wu PC, Mason RS, Posen S. Osteomalacia secondary to osteosarcoma: a case report. J Bone Joint Surg Am 1989; 71:288-92.
11. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-8.
12. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001;60:2079-86.
13. Shimada T, Mizutani S, Muto T, etal. Cloning and characterization of FGF23 as a causative factor oftumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001;98:6500-5.
14. Schiavi SC, Moe OW. Phosphatonins: a new class of phosphate-regulating proteins. Curr Opin Nephrol Hypertens 2002;11:423-30.